Heart Health and COVID-19: Fighting Inflammation May be Key -- SECFilings.com

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Redondo Beach, California--(Newsfile Corp. - July 15, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the connection between heart disease, COVID-19, and inflammation. Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a pharmaceutical development company focused on heart health, is developing therapies to address the intertwined effects of these three conditions with the hope of improving outcomes for COVID-19 patients.

It is no secret that people with underlying health conditions are the most vulnerable potential COVID-19 patients. Prominent among these hazardous underlying conditions is heart disease. According to the Centers for Disease Control, patients with heart failure, coronary artery disease, and other heart conditions are particularly at risk for severe illness from the virus.

The connection between COVID-19 and the heart is, along with many other aspects of this novel disease, slowly coming into focus. There is mounting evidence that COVID-19 may also produce heart injury in patients, and excessive inflammation (sometimes resulting in a fatal cytokine storm) may be the culprit. This scientific article lays out the case pretty clearly: treating heart inflammation is a key to avoiding catastrophic results.

Cardiol Therapeutics, already focused on developing therapies for heart conditions, is forging ahead in this area. Cardiol filed a new patent application covering the use of cannabidiol (CBD) to improve the outcome of patients with COVID-19. The company has already planned to study CBD as a primary active in the treatment for heart failure and acute myocarditis. With all of the evidence surrounding heart disease and negative COVID-19 outcomes, Cardiol is naturally progressing its research to determine whether CBD can help a) improve outcomes for patients with pre-existing heart conditions or risk factor for heart disease, and b) decrease the occurrence of cardiovascular complications in such patients.

Inflammation is the Enemy

Chronic heart failure (HF) is common, with an estimated six million adults suffering from the disease in Canada and the United States. Approximately 50% of patients with HF have a condition known as HF with preserved ejection fraction (HFpEF), wherein the contraction of the heart remains relatively normal, but there is an abnormality in the filling of the heart during the relaxation phase. Over the last twenty years, there have been no major advancements in the treatment of this form of HF. Current standard of care is the use of diuretics to decrease inflammation, and there is no known cure. Inflammation in the heart tissue leads to increased production of cytokines, increased oxidative stress, death of heart cells, and eventually to the creation of fibrosis, which leads to increased stiffness of the heart tissues that further exacerbates the problem. In this way, the body creates a destructive inflammatory feedback loop. It is similar to the way doctors discuss the often-fatal cytokine storms resulting from COVID-19.

Acute myocarditis is another problematic form of heart disease and is the most common cause of sudden cardiac death in people under the age of 35. It is most often caused by a viral infection followed by the body's inflammatory response, similar in many ways to what doctors are seeing with COVID-19 patients.

Cardiol is advancing studies on the efficacy of targeted CBD treatments for both of these heart conditions. The targeting mechanism consists of proprietary nanotherapeutics technology that enables water-insoluble drugs (like fat-based CBD) to be distributed in the bloodstream and accumulate in the affected heart tissues. In March, the company's researchers presented evidence that these nanoparticles accumulated in diseased heart tissues in excess of 100 times more than in the healthy control group. Clearly, Cardiol has the technology to effectively deliver active pharmaceutical ingredients to targeted tissues.

Why CBD?

With the decades-long prohibition of cannabis and minimal scientific research into the plant, there is a lot to be discovered about the potential benefits of the wide variety of active ingredients, called cannabinoids, prevalent in cannabis. One in particular, cannabidiol (CBD), has shown potential for treating conditions ranging from epilepsy to sleep disorders to PTSD. It is available in copious amounts from both cannabis and hemp plants and is not psychoactive.

Research shows that "CBD reduces the levels of pro-inflammatory cytokines, inhibits T cell proliferation, induces T cell apoptosis, and reduces migration and adhesion of immune cells." These are just the types of actions needed to treat heart disease, as well as to mitigate an over-responsive immune system. Here are some more sources for research on the topics of heart failure,inflammation, and CBD.

Cardiol Putting It Together

Cardiol Therapeutics is combining a number of threads to attack heart disease, and now COVID-19. It starts with the experienced team dedicated to improving heart patient outcomes. The company is partnering with key international research organizations, including the renowned Houston Methodist DeBakey Heart & Vascular Center. Cardiol also partners with Purisys, LLC and Dalton Pharma Services for the formulation and production of its own proprietary pure pharmaceutical CBD, which it uses in its research and plans to launch commercially to Canadian medical cannabis patients.

The nanotechnology ensures targeted delivery of the CBD to affected tissues, overcoming a common problem of cannabinoid and other lipid-based therapies. The CBD it uses is produced in cGMP and FDA-approved facilities, legitimizing the drug, and perhaps increasing the chances it could be approved should the research bear fruit. The recent intellectual property filing could serve to protect Cardiol should it find, as preliminary research indicates, that its CBD therapies help those with heart conditions, and by extension help COVID-19 patients achieve better outcomes.

A look at the development of some comparable companies can shine some light on Cardiol's potential. GW Pharma's cannabis-derived Epidiolex was approved by the FDA in 2018 for the treatment of two rare forms of epilepsy. The company had previously introduced Sativex, a cannabis-derived oral spray for the relief of multiple sclerosis (MS) symptoms and cancer-related neuropathic pain. GW's incremental success in developing and getting approval for these drugs led to stock appreciation from $10 in the summer of 2013, to a high of about $180 in May 2019 (currently around $130).

More recently, and in the heart disease arena, MyoKardia announced positive Phase 3 results for its candidate to treat obstructive hypertrophic cardiomyopathy (HCM). The announcement triggered a run up of the company's stock, from approximately $60 to $120 (currently around $90). Earlier results had similar effects, with Phase 1 safety trials pushing the stock from $10 to $20, followed by Phase 2 results catapulting the stock over $40 in 2017.

Cardiol recently closed a financing of $17.25 million, intended to support its clinical development program as well as the commercial launch of its pharmaceutical CBD product. The company also brought on noted CNBC Fast Money commentator Steven Grasso as business advisor to raise its profile in the U.S. investment community. The table is set. Keep an eye out for further developments from Cardiol Therapeutics as the company seeks to emulate the success of its peers in both the heart and CBD fields.

Please follow the link to read the full article: http://www.secfilings.com/news/heart-health-and-covid19-fighting-inflammation-may-be-key-136

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members.

Disclaimer

SECFilings.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.secfilings.com (the 'Site') is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. SECFilings.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. SECFilings.com received compensation for producing and presenting high quality and sophisticated content on SECFilings.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns SECFilings.com, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://secfilings.com/Disclaimer.aspx.

Paul Archie
406.862.2242
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59832

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).